Sign In
20 Jun 2024 07:00
20 June 2024
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Exercise of Options and Total Voting Rights
Brighton, United Kingdom - 20 June 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, announces that it has issued and allotted 258,748 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by a former director.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 25 June 2024 ("Admission").
Following Admission, the Company will have a total of 95,770,611 Ordinary Shares in issue. Shareholders may use this figure of 95,770,611 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
- END -
For further information, please contact:
Destiny Pharma plc Chris Tovey, CEOShaun Claydon, CFO+44 (0)1273 704 440 pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
For further information on the company, please visit www.destinypharma.com
Follow the stocks
